Related Experiment Video
Updated: Jul 19, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Janus kinase inhibitors for alopecia areata
Brett A King1, Brittany G Craiglow1
1Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Abstract:
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and considerations regarding differences among JAK inhibitors, safety, and patient selection.
Related Concept Videos
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
cAMP-dependent Protein Kinase Pathways

